Several studies have found that ccRCC which responded better to anti-VEGF treatment showed lower levels of immune checkpoint molecules, similar to the immune-silenced subtype of ccRCC described above (51, 52). Here, VEGFA is linked to nonpapillary renal cell carcinoma.